Qorvo Inc. (QRVO): QRVO will be a big player in the 5G spac...

Stockman1010101 · 2020-01-13T00:48:38.6970000Z

QRVO will be a big player in the 5G space this year. Anybody here interested please respond with your outlook on it. Thanks.

Play Episode

5min

Proactive - Interviews for investors

Zero Candida begins trading on OTCQB, advances AI-driven women’s health solutions

Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to announce that the company’s common shares are now trading on the OTCQB Venture Market under the ticker "ZCTFF", alongside its existing listings on the TSX Venture Exchange and Frankfurt Stock Exchange. Ben-Haroosh emphasized that this milestone expands Zero Candida’s market presence, enhances strategic partnerships, and broadens the company’s investor base to support its AI-driven medical technology innovations. Zero Candida is pioneering a novel, non-drug treatment for Vulvo-Vaginal Candidiasis (VVC)—a condition affecting approximately 75% of women globally, with rising resistance to conventional antifungal treatments. The company is developing a tampon-like medical device that utilizes artificial intelligence and therapeutic blue light at a precise wavelength and intensity to eradicate Candida fungus. Early proof-of-concept (POC) studies have demonstrated an impressive 99.999% success rate in treating infections. With drug-resistant cases of recurrent VVC on the rise, Zero Candida’s innovative approach offers a groundbreaking alternative to existing treatments. Zero Candida has completed its preclinical trials with what Haroosh said was “100% safety,” and is preparing for clinical trials by the end of 2025, with market entry targeted after 2026 following FDA approval. #proactiveinvestors #zerocandida #tsxv #zct #WomensHealth #CandidaTreatment #MedicalDevice #Telemedicine #AIinHealthcare #NonDrugTherapy #OTCQB #HealthcareInnovation #FungalInfection

Proactive - Interviews for investors

St George Mining’s dual track growth plan

St George Mining Ltd executive chairman John Prineas talked with Kerry Stevenson at Proactive about the company's recent acquisition of the Araxá niobium and rare earths project in Brazil. The deal, completed in February, provides St George with an advanced-stage project with high-grade niobium and rare earth elements. Prineas highlighted niobium’s strategic importance, noting that it is primarily used to strengthen steel, with additional applications in medical technology, batteries, and defence. He emphasised the commodity's stable pricing due to limited global supply. The company secured A$20 million in funding to advance the project and is preparing a JORC-compliant mineral resource estimate, expected in the coming weeks. The existing data, based on historical drilling, indicates a 20-year mine life and a US$956 million NPV under a previous non-JORC study. St George aims to optimise the project for niobium, conduct further drilling, and expand the resource. Prineas also addressed Brazil's mining jurisdiction, highlighting strong government support and agreements to expedite approvals. The company is pursuing a dual-track strategy, progressing toward development while ramping up exploration drilling to expand the resource base. Stay tuned for more updates! Visit Proactive's YouTube channel for more interviews, and don’t forget to like, subscribe, and turn on notifications. #StGeorgeMining #ASXSGQ #Niobium #RareEarths #MiningStocks #JORC #BrazilMining #CriticalMetals #ResourceInvestment #BatteryMetals

Proactive - Interviews for investors

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth

Protalix BioTherapeutics Chairman Dr Eliot Forster joined Steve Darling from Proactive to discuss the company’s innovative approach to drug manufacturing, which leverages plant cells instead of traditional mammalian cells. This unique method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech industry. Forster highlighted the company's commercial success, noting that Protalix has two marketed products through partnerships with Pfizer and Chiesi. He emphasized the company’s strong financial position, having repaid all outstanding debt and operating without warrants, reinforcing its ability to drive long-term growth. A key focus of the discussion was PRX-115, Protalix’s experimental treatment for severe gout. In 2024, the company completed a first-in-human study with promising results. A Phase 2 trial is scheduled for 2025, and Forster expressed optimism about its potential to address a significant unmet medical need. Beyond PRX-115, Forster detailed the company’s strong financial performance in 2024, describing it as a breakthrough year fueled by increased revenue from its three business streams. Looking ahead, Protalix is actively advancing treatments for rare diseases, including renal conditions, as it continues to expand its innovative pipeline. #proactiveinvestors #protalixbiotherapeutics #nyseamerican #plx #Biotech #DrugDevelopment #GoutTreatment #Pharmaceuticals #EliotForster #PRX115 #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

KRM22 CEO on risk management, compliance & growth plans

KRM22 CEO Dan Carter talked with Proactive's Stephen Gunnion about the company’s mission to provide integrated risk management solutions for capital markets. Founded in 2018, KRM22 has developed a suite of tools that help firms manage trading and corporate risk more efficiently. Carter explained that capital markets have traditionally relied on siloed risk tools. KRM22 has worked to integrate these tools into a holistic platform. The company’s solutions cover intraday risk management, pre-trade limit controls, market surveillance, and enterprise risk tracking. “We've created a digitised risk register that helps bring those data points together and validate assessments,” he said. The discussion also covered the impact of regulatory changes post-Covid. Carter highlighted that regulators are now scrutinising risk management practices more closely. He emphasised that KRM22’s tools help firms demonstrate compliance, reducing the risk of regulatory penalties. On growth, Carter noted that KRM22’s annual recurring revenue (ARR) is now around £7 million, with a recent customer contract further strengthening the company’s financial position. Looking ahead, KRM22 is exploring AI-driven enhancements, particularly in market surveillance, to detect potential compliance issues before they become violations. For more insights, watch the full interview. Don't forget to like the video, subscribe to Proactive's channel, and turn on notifications for updates! #KRM22 #RiskManagement #CapitalMarkets #TradingRisk #RegTech #MarketSurveillance #FinancialCompliance #AIinFinance #CorporateRisk #Investing

Followers	226
Posts	15781
Boards Moderated	0
Alias Born	03/01/2013

Volume:	2,241,767
Day Range:	71.10 - 73.93
Bid:	70.25
Ask:	71.50
Last Trade Time:	7:05:19 PM EDT
Total Trades:	33,192

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

QRVO Detailed Quote

Recent QRVO News

More QRVO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent QRVO News

Go Ad-Free